Physicians and researchers from Winship Cancer Institute of Emory University will present new and late-breaking data at the 46th San Antonio Breast Cancer Symposium in San Antonio, Dec. 5-9, 2023.
Co-sponsored by the American Association for Cancer Research and the Mays Cancer Center at UT Health San Antonio, the annual symposium brings together about 10,000 clinicians and scientists and is the largest scientific gathering on breast cancer research.
"It is exciting to see the wide range of important data that Winship investigators are presenting at the 2023 San Antonio Breast Cancer Symposium," said Kevin Kalinsky, MD, MS, director of the Glenn Family Breast Center at Winship. "This research ranges from public health studies to understanding tumor biology to novel clinical trials to treat our patients with breast cancer."
Winship researchers will participate in 18 presentations as session chairs, oral and poster presenters and speakers. Studies will highlight the latest clinical and translational research, offering new insights into breast cancer prevention, diagnosis, treatment and survivorship.
Winship-led presentations and sessions at SABCS 2023
Wednesday, December 6
Poster Session 1 | 12:00 p.m. - 2:00 p.m.
- Cathy Graham, MD - "PO1-02-11 Characterization of MammaPrint UltraLow Risk tumors in more than 1400 patients from the real-world evidence FLEX study"
Concurrent Poster Spotlight Session Block #3 | 5:30 p.m. - 6:30 p.m.
- Kevin M. Kalinsky, MD, MS - PS08-10 Discussant
Poster Session 2 | 5:00 p.m. - 7:00 p.m.
- Ruth Sacks, MD - "PO2-02-04 The Impact of Statins on Breast Cancer Specific Mortality in a Diverse Patient Population with Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer"
- Demetria Smith-Graziani, MD, MPH - "PO2-10-01 Discrimination, Trust, and Pain Outcomes Among Black Women with Early-Stage Breast Cancer After Mastectomy"
- Lauren McCullough, PhD, MPH - "PO2-11-12 The power of storytelling to heal, build community, and understand the experiences of Black breast cancer survivors"
- Rebecca Nash - "PO2-14-07 Association between expression of androgen receptor in tumor tissue and risk of breast cancer recurrence among premenopausal Danish women"
- Manali Bhave, MD - "PO2-16-05 ESR1 mutations (ESR1mut) in HR(+)HER2(-)patients with metastatic breast cancer (MBC): prevalence along treatment course and predictive value for endocrine therapy (ET) resistance in real world practice"
Thursday, December 7
General Session 2, Hall 1 | 8:15 a.m. - 11:15 a.m.
- Reshma Jagsi, MD, DPhil - "GS02-08 Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients age 50-69 with genomically-selected favorable Stage I breast cancer”
Poster Session 3 | 12:00 p.m. - 2:00 p.m.
- Xiaoxian Li, MD, PhD - "PO3-13-03 RNAScope: a practical approach and promising alternative to immunohistochemistry to quantify HER2 expression in breast cancer"
- Jane Meisel, MD - "PO3-16-09 Real-World Experience with Trastuzumab Deruxtecan at a Diverse NCI Comprehensive Cancer Center"
Clinical Controversies, Stars at Night Ballroom 3-4 | 2:00 p.m. - 3:00 p.m.
- Kevin Kalinsky, MD, MS - "Biology or stage? Tailoring treatment for premenopausal women with nodal involvement, but low oncotype"
Friday, December 8
Poster Session 4 | 5:00 p.m. - 7:00 p.m.
- Sunil Badve, MD - "PO4-16-03 Ectopic expression of lineage-specific transcription factors in Breast Cancer"
- Ruth Sacks, MD - "PO4-20-04 A Randomized Window of Opportunity Study of Preoperative Letrozole and Simvastatin Versus Letrozole Alone in Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer"
- Mylin Torres, MD - "PO4-27-08 A Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer Patients"
Poster Session 5 | 12:00 p.m. - 2:00 p.m.
- Lizzie Huckaby, BSN - "PO5-10-06 A Pilot Study for Clinical Research Nurse Navigation at an Urban NCI-Designated Comprehensive Cancer Center"
- Sarah Wood, MD - "O5-17-01 Pre-treatment tumor infiltrating lymphocytes are associated with higher likelihood of pathologic complete response Among Black women with TNBC receiving neoadjuvant chemoimmunotherapy"
- Mayar Allam - "PO5-23-09 Metabolic alterations in Estrogen Receptor-positive breast cancer contributing to CDK4/6 resistance"
Saturday, December 9
Navigating Success: Women’s Career Development, Room 304 | 9:00 a.m. - 12:00 p.m.
- Reshma Jagsi, MD, DPhil - "Evidence-based strategies to address systemic barriers facing women researchers"